Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia
Franco Locatelli, James A. Whitlock, Christina Peters, Christiane Chen‐Santel, Victoria Chia, Robyn M. Dennis, Kenneth Heym, Aaron J. Katz, Michael A. Kelsh, Richard Sposto, Huakang Tu, Catherine Tuglus, Anupam Verma, Luciana Vinti, Jennifer J. Wilkes, Nathalya Zubarovskaja, Gerhard Zugmaier, Arend von Stackelberg, Weili Sun
Abstract
Relapse and, less frequently, refractoriness to front-line therapy are the main causes of treatment failure in childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL), occurring in 15-20% of patients Prognosis after relapse depends primarily on the time elapsing between diagnosis and relapse, site of relapse, and disease immunophenotypes [2]; unfortunately, many of these patients further relapse despite receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT)